Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen

T. (Tim) Bognàr*, J. S. (Jurjen) Kingma, E. H. (Erin) Smeijsters, K. C. M. (Kim) van der Elst, C. T. M. (Klaartje) de Kanter, C. A. (Caroline) Lindemans, A. C. G. (Toine) Egberts, I. H. (Imke) Bartelink, A. (Arief) Lalmohamed

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Busulfan exposure has previously been linked to clinical outcomes, hence the need for therapeutic drug monitoring (TDM). Study objective was to evaluate the effect of day 1 TDM-guided dosing (regimen d1) versus days 1 + 2 TDM-guided dosing (regimen d1 + 2) on attaining adequate busulfan exposure. In this observational study, we included all children receiving busulfan-based allogeneic hematopoietic cell transplantation. Primary outcome was the percentage of patients achieving busulfan target attainment in both TDM regimens. Secondary outcomes were the variance in busulfan exposure and day-4 clearance (Cl day4) estimates between both TDM regimens and dosing day 1 and 2. In regimen d1, 84.3% (n = 91/108) attained a therapeutic busulfan exposure, while in regimen d1 + 2 a proportion of 90.9% was found (n = 30/33, not-significant). Variance of Cl day4 estimate based on busulfan day 2 concentrations was significantly smaller than the variance of Cl day4 estimates based on day 1 concentrations (p < 0.001). Therefore, day 1-guided TDM (pharmacometric model-based) of busulfan may be sufficient for attaining optimal target exposure, provided that subsequent TDM is carried out if required. However, performing TDM on subsequent days may be beneficial, as measurements on day 2 seemed to reduce the variance in the estimated clearance as compared to day 1 sampling.

Original languageEnglish
JournalBone Marrow Transplantation
Early online date2023
Publication statusE-pub ahead of print - 2023

Cite this